Problem with generic meds

Changes in color, shape may lead to interruptions in use

December 31, 2012 |
Editor's Pick

Image courtesy of Cerner Mutum

Changes in the appearance of drugs may cause patients to stop taking them. Pictured (at top) is Prozac (fluoxetine) as it appears when manufactured by Lilly. Below it are four generic versions of fluoxetine. Based on research, the color of the medication seems to have the greatest impact on patient usage.

Generic medications currently account for more than 70 percent of prescriptions dispensed. However, although generic drugs are clinically bioequivalent to the brand-name version, they often differ in their physical characteristics, such as color and shape. Researchers from Harvard-affiliated Brigham and Women’s Hospital (BWH) have found that some patients who receive generic drugs that vary in their color are over 50 percent more likely to stop taking the drug, leading to potentially important and potentially adverse clinical effects.

“Pill appearance has long been suspected to be linked to medication adherence, yet this is the first empirical analysis that we know of that directly links pills’ physical characteristics to patients’ adherence behavior,” explained Aaron S. Kesselheim, assistant professor of medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics at BWH, and principal investigator of this study. “We found that changes in pill color significantly increase the odds that patients will stop taking their drugs as prescribed.”

The researchers conducted a case-control study of patients taking antiepileptic drugs and compared the odds that patients who did not refill their medication had been given pills that differed in color or shape from the prior prescriptions. Using a large national database of filled prescriptions, when the researchers identified a break in the patient’s use of the drug, they looked at the previous two prescription fillings to see if they were the same color and shape. They found that interruptions in the prescription filling occurred significantly more frequently when the pills had different color. Interruptions in antiepileptic drug use for even a few days can raise the risk of seizure and have important medical and social consequences for patients.

These findings offer important take-home messages for physicians, pharmacists, and patients. As Kesselheim explained, “Patients should be aware that their pills may change color and shape, but that even differently appearing generic drugs are approved by the FDA as being bioequivalent to their brand-name counterparts and are safe to take. Physicians should be aware that changes in pill appearance might explain their patients’ nonadherence. Finally, pharmacists should make a point to tell patients about the change in color and shape when they change generic suppliers.”

Researchers acknowledge that medication adherence is a multifaceted issue, but suggest that taking steps to permit (or even require) similarity in pill appearance among bioequivalent brand-name and generic drugs may offer a relatively simple way to contribute to better adherence.

Changes in the appearance of drugs may cause patients to stop taking them. Pictured (at top) is Prozac (fluoxetine) as it appears when manufactured by Lilly. Below it are four generic versions of fluoxetine. Based on research, the color of the medication seems to have the greatest impact on patient usage.

Three weeks after a remarkably nasty presidential election, emotions remain raw, as was evidenced when the Trump and Clinton camps met for the first time at Harvard Kennedy School for a debriefing conference this week.

A new Harvard center on health and happiness had its academic coming-out party Friday, hosting a daylong symposium that highlighted what science does and doesn’t say about the interaction of health and happiness, and identifying pathways where investigators should probe next.

Harvard researchers at Dana-Farber Cancer Institute find that aspirin therapy can extend the life of colorectal cancer patients whose tumors carry a mutation in a key gene, but it has no effect on patients who lack the mutation.